Background

For patients not receiving autologous stem cell transplantation (ASCT), bortezomib-based regimens such as CyBorD (bortezomib with cyclophosphamide and dexamethasone), BMDex (bortezomib with melphalan and dexamethasone), VD have been first-line treatment in AL amyloidosis over the last few years. Changing trends in first-line treatment (MDex to bortezomib-based regimens) significantly improved responses over time. However, several studies showed early death (<6 months) rate have been unchanged or rather higher in bortezomib-based group. The purpose of this study is to investigate the efficacy of bortezomib-based regimens for patients with newly diagnosed AL amyloidosis

Patients and methods

A total 115 patients with newly diagnosed AL amyloidosis who did not receive ASCT were analyzed. They were registered from two cohorts; retrospective cohort (April 1995 - November 2011, n=27) and prospective cohort (March 2012 - February 2017, n=88). Patients were classified into two groups according to first-line treatment; bortezomib-based regimens (VMP, n=39; Bortezomib and dexamethasone, n=12; CyBorD, n=8; BMDex, n=2; Bortezomib with thalidomide and dexamethasone, n=1) and alkylator and dexamethasone-based regimens (MDex, n=35; Cyclophosphamide and dexamethasone, n=18). The primary endpoint was early death rate and secondary endpoints were overall response rate, overall survival, and progression free survival.

Results

At baseline characteristics, bortezomib-based group showed significantly higher risk of cardiac involvement and more advanced stage. Although bortezomib-based group was in higher risk, there were no significant differences in early death rate (22.5% vs 18.8%, p=0.790). The rate of ≥ VGPR (very good partial response) and overall response rate were significantly higher in bortezomib-based group (50% vs 22.3% and 63.2% vs 28.9%, respectively). However overall survival and progression free survival represented no significant differences by two groups (p=0.916 and p=0.798).

Conclusion

In this retrospective analysis bortezomib-based regimens in newly diagnosed AL amyloidosis showed higher efficacy and similar early death rate and survival in spite of higher cardiac risks in comparison with alkylating agents with dexamethasone.

graphic
View largeDownload slide
Disclosures

Kim: J&J: Research Funding; Mundipharma: Research Funding; Novartis: Research Funding; Kyowa-Kirin: Research Funding; Celltrion, Inc: Consultancy, Honoraria; Roche: Research Funding; Takeda: Research Funding; Donga: Research Funding.

Topics:
alkylating agents, autologous stem cell transplant, bortezomib, dexamethasone, immunoglobulin deposition disease, primary amyloidosis, cyclophosphamide, cardiovascular findings, melphalan, partial response

Author notes

*

Asterisk with author names denotes non-ASH members.

© 2017 by The American Society of Hematology
2017
Sign in via your Institution